Clinical colorectal cancer最新文献

{"title":"Systemic Therapy for Pancreatic Neuroendocrine Tumors","authors":"Margaret Wheless ,&nbsp;Satya Das MD, MSCI","doi":"10.1016/j.clcc.2022.08.003","DOIUrl":"10.1016/j.clcc.2022.08.003","url":null,"abstract":"<div><p><span><span>Patients with metastatic or advanced pancreatic neuroendocrine tumors (NETs) carry poorer prognoses relative to patients with other </span>NETs<span> due to bulkier and often, more proliferative baseline disease. Patients with these tumors also possess more approved treatment options relative to patients with other NETs, making therapeutic sequencing nuanced. As such, defining optimal therapeutic sequencing and developing more potent cytoreductive treatments for patients are significant areas of research need in the field. Herein this review, we discuss the current systemic therapy landscape, our approach to therapeutic sequencing in the clinic and ongoing studies seeking to define optimal sequencing of systemic therapies, and novel therapeutics in development, for patients with pancreatic NETs. We limit the scope of this latter topic to agents with preclinical or clinical rationale over the last 8 years to provide a contemporary view of the </span></span>drug<span><span> development landscape and focus primarily on new types of peptide receptor<span> radionuclide therapy, anti-vascular endothelial growth factor </span></span>receptor tyrosine kinase<span> inhibitors and anti-vascular endothelial growth receptor tyrosine kinase inhibitor plus immunotherapy combinations.</span></span></p></div>","PeriodicalId":10373,"journal":{"name":"Clinical colorectal cancer","volume":"22 1","pages":"Pages 34-44"},"PeriodicalIF":3.4,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9505134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Single-Agent Neoadjuvant Immunotherapy With a PD-1 Antibody in Locally Advanced Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer","authors":"Fengyun Pei ,&nbsp;Jingjing Wu ,&nbsp;Yandong Zhao ,&nbsp;Wan He ,&nbsp;Qijun Yao ,&nbsp;Meijin Huang ,&nbsp;Jun Huang","doi":"10.1016/j.clcc.2022.11.004","DOIUrl":"10.1016/j.clcc.2022.11.004","url":null,"abstract":"<div><h3>Background</h3><p>PD-1 blockade has been recommended as first-line therapy for nonresectable or metastatic mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) colorectal cancer (CRC). However, the safety and efficacy of neoadjuvant PD-1 blockade immunotherapy for locally advanced dMMR/MSI-H CRC remain unclear.</p></div><div><h3>Patients and Methods</h3><p>From June 2020 to June 2022, 11 locally advanced dMMR/MSI-H CRC patients treated at the Sixth Affiliated Hospital of Sun Yat-sen University (Guangzhou, China) were enrolled. All patients received 6 sintilimab (Innovent, LTD) injections (200 mg/injection, every 3 weeks) before radical laparoscopic resection. The patient clinical and pathological data were analyzed retrospectively.</p></div><div><h3>Results</h3><p>dMMR was confirmed by immunohistochemistry for all patients. However, polymerase chain reaction (PCR) or next-generation sequencing confirmed MSI-H for only 90.9% (10/11) of the patients, while 1 patient had microsatellite stable (MSS) disease. After 6 injections of neoadjuvant anti-PD-1 therapy, 90.9% (10/11) of the patients (those confirmed to have dMMR and MSI-H disease) achieved pathological complete response (pCR). The other patient, who achieved major pathological response with residual tumor &lt;1%, had dMMR but MSS disease. No grade 3 or above immunotherapy-related adverse events occurred [Common Terminology Criteria for Adverse Events ; version 5.0]. Overall, 72.7% (8/11) of the patients had grade 1-2 immunotherapy-related adverse events . No operational mortality or complications occurred within 30 days after surgery.</p></div><div><h3>Conclusion</h3><p>Single-agent neoadjuvant PD-1 antibody immunotherapy was safe and effective in locally advanced dMMR/MSI-H CRC. Dual confirmation of MMR and MSI status by immunohistochemistry and next-generation sequencing or PCR is necessary for dMMR/MSI-H CRC patients before immunotherapy. The immunotherapy regimen used in this study deserves further validation in phase II and III clinical studies.</p></div>","PeriodicalId":10373,"journal":{"name":"Clinical colorectal cancer","volume":"22 1","pages":"Pages 85-91"},"PeriodicalIF":3.4,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9153543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systemic Therapy for Patients With Pancreatic Cancer: Current Approaches and Opportunities for Novel Avenues Toward Precision Medicine","authors":"Ruveyda Ayasun ,&nbsp;Turcin Saridogan ,&nbsp;Ola Gaber ,&nbsp;Ibrahim Halil Sahin","doi":"10.1016/j.clcc.2022.11.001","DOIUrl":"10.1016/j.clcc.2022.11.001","url":null,"abstract":"<div><p><span>Pancreatic ductal adenocarcinoma<span><span> (PDAC) has a dismal prognosis with a 5-year overall survival of 11%. The disease is usually diagnosed at advanced stages, and systemic chemotherapy is the standard-of-care treatment<span> for the majority of patients with PDAC. Although novel treatment options, such as targeted therapy and </span></span>immunotherapy<span>, have achieved substantial progress leading to practice-changing results, with FDA approvals for several solid tumors so far, the progress achieved for PDAC is relatively limited. Recent studies uncovered potential therapeutic targets for patients with PDAC, and potential therapeutic opportunities are currently being further examined. Herein, we review recent advances in systemic therapy regimens, including </span></span></span>cytotoxic agents<span>, targeted therapies, immunotherapy, and novel therapeutic options for managing patients with PDAC. We also elaborate on molecular profiling to guide treatment and existing therapeutic opportunities that may further advance the clinical care of patients with this devastating disease.</span></p></div>","PeriodicalId":10373,"journal":{"name":"Clinical colorectal cancer","volume":"22 1","pages":"Pages 2-11"},"PeriodicalIF":3.4,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9159351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stereotactic Ablative Radiation Therapy for Colorectal Liver Metastases","authors":"Ronan L McDermott ,&nbsp;Emma M Dunne ,&nbsp;Yizhou Zhao ,&nbsp;Alanah Bergman ,&nbsp;Mitchell CC Liu ,&nbsp;Devin Schellenberg ,&nbsp;Roy MK Ma","doi":"10.1016/j.clcc.2022.10.006","DOIUrl":"10.1016/j.clcc.2022.10.006","url":null,"abstract":"<div><h3>Introduction</h3><p>Stereotactic Ablative Radiation Therapy (SABR) is a therapeutic option for patients with inoperable oligometastatic colorectal carcinoma (CRC). Given the scarcity of prospective data on outcomes of SABR for metastatic CRC, this study aims to review SABR outcomes and determine predictive factors of local control (LC) and survival in patients with liver metastases from CRC.</p></div><div><h3>Materials and Methods</h3><p>A retrospective review of SABR for CRC liver metastases between 2011 and 2019 was undertaken. Endpoints included LC, overall survival (OS), progression-free survival (PFS) and time to restarting systemic therapy. Univariate (UVA) and multivariable analyses (MVA) were performed to identify predictive factors.</p></div><div><h3>Results</h3><p>Forty-eight patients were identified. The total number of tumors treated was 58. Median follow-up was 26.6 months. LC at 1, 2 and 3 years was 92.7%, 80.0%, and 61.2% respectively. Median time to local failure was 40.0 months (95% CI 31.8-76.1 months). Median OS was 31.9 months (95% CI 20.6-40.0 months). OS at 1, 2, and 3 years was 79.2%, 61.7%, and 44.9% respectively. Thirty-three patients (69%) restarted systemic therapy after completion of SABR. Median time to restarting chemotherapy was 11.0 months (95% CI 7.1-17.6 months). Systemic therapy free survival at 1, 2, and 3 years was 45.7%, 29.6%, and 22.6% respectively. On MVA, inferior LC was influenced by GTV volume ≥40 cm³ (HR: 3.805, 95% CI 1.376-10.521, <em>P</em> = .01) and PTV D100% BED &lt;100 Gy₁₀ (HR 2.971, 95% CI 1.110-7.953; <em>P</em> = .03). Inferior OS was associated with PTV volume ≥200 cm³ (HR 5.679, 95% CI 2.339-13.755; <em>P</em> &lt; .001).</p></div><div><h3>Conclusion</h3><p>SABR is an effective therapeutic option for selected patients with CRC liver metastases providing acceptable LC within the first 2 years. In many cases, it provides meaningful chemotherapy-free intervals. Higher biological effective doses are required to enhance LC.</p></div>","PeriodicalId":10373,"journal":{"name":"Clinical colorectal cancer","volume":"22 1","pages":"Pages 120-128"},"PeriodicalIF":3.4,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9151268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pathologic Implications of Magnetic Resonance Imaging-detected Extramural Venous Invasion of Rectal Cancer","authors":"Hyun Gu Lee ,&nbsp;Chan Wook Kim ,&nbsp;Jong Keon Jang ,&nbsp;Seong Ho Park ,&nbsp;Young Il Kim ,&nbsp;Jong Lyul Lee ,&nbsp;Yong Sik Yoon ,&nbsp;In Ja Park ,&nbsp;Seok-Byung Lim ,&nbsp;Chang Sik Yu ,&nbsp;Jin Cheon Kim","doi":"10.1016/j.clcc.2022.10.005","DOIUrl":"10.1016/j.clcc.2022.10.005","url":null,"abstract":"<div><h3>Background</h3><p><span><span>Extramural venous invasion (EMVI) is a poor prognostic factor in </span>rectal cancer. Recent advances in magnetic resonance imaging (MRI) allow for the detection of EMVI before surgery. This study aimed to analyze the correlations between MRI-detected EMVI (MR-EMVI) and pathologic parameters </span>in patients with rectal cancer.</p></div><div><h3>Materials and Methods</h3><p>This study retrospectively analyzed 721 patients who underwent radical resection<span> for locally advanced rectal cancer between 2018 and 2019 at the Asan Medical center. All patients underwent an MRI before surgery. The lesions of patients who received neoadjuvant chemoradiation therapy (CRT) were evaluated by MRI before and after the neoadjuvant CRT.</span></p></div><div><h3>Results</h3><p><span>Of the 721 patients, 118 (16.4%) showed a positive MR-EMVI, which significantly correlated with advanced pathologic T-category and N-category, extranodal extension, poor differentiation, lymphatic invasion, venous invasion, and perineural invasion. In addition, MR-EMVI was an independent factor for predicting the pathologic nodal status (OR 3.476, 95% CI, 2.186-5.527, </span><em>P</em><span> &lt; .001). Patients with a positive MR-EMVI had a sensitivity of 28.0% and specificity of 91.9% for predicting regional lymph node metastasis, whereas the MR-N category had a sensitivity of 88.7% and specificity of 30.6%. Patients whose MR-EMVI changed from positive to negative after neoadjuvant CRT had no significant differences in pathologic parameters except for lymphatic invasion with patients who were negative before and after neoadjuvant CRT.</span></p></div><div><h3>Conclusion</h3><p>MR-EMVI correlated with aggressive pathologic features, which indicated a poor prognosis. MR-EMVI may be a complementary imaging biomarker for predicting nodal status and evaluating tumor response to neoadjuvant CRT.</p></div>","PeriodicalId":10373,"journal":{"name":"Clinical colorectal cancer","volume":"22 1","pages":"Pages 129-135"},"PeriodicalIF":3.4,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9505705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Institutional Universal Microsatellite-Instability (MSI) Reflex Testing on Molecular Profiling Differences Between Younger and Older Patients with Colorectal Cancer","authors":"Ellery Altshuler ,&nbsp;Aaron J. Franke ,&nbsp;William Paul Skelton IV ,&nbsp;Michael Feely ,&nbsp;Yu Wang ,&nbsp;Ji-Hyun Lee ,&nbsp;Thomas Read ,&nbsp;Krista Terracina ,&nbsp;Xiang-Yang Lou ,&nbsp;Yunfeng Dai ,&nbsp;Thomas J. George","doi":"10.1016/j.clcc.2022.09.004","DOIUrl":"10.1016/j.clcc.2022.09.004","url":null,"abstract":"<div><h3>Introduction</h3><p>DNA mismatch repair<span> deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC) is found in about 15% of early-stage diseases<span> and 5% of metastatic diseases. We reviewed a large, single-institutional database after implementation of universal reflex dMMR/MSI-H testing in CRC to compare profiles of younger (≤50) and older (&gt;50) patients.</span></span></p></div><div><h3>Patients and Methods</h3><p>Between 2009 and 2017, all patients diagnosed with CRC at the University of Florida underwent reflex somatic tumor testing for dMMR by immunohistochemistry<span> (MLH1, PMS2, MSH2, MSH6), MSI by PCR<span>, and Next-Generation Sequencing. Statistical analysis was conducted with 2-sample comparison tests and logistic regression models.</span></span></p></div><div><h3>Results</h3><p>There were 375 patients included in the final analysis. Patients were grouped as younger (ages ≤50 years-old; n = 80) or older (&gt;50 years-old; n = 295). Compared to tumors from older patients, tumors from younger patients were less likely to be dMMR/MSI-H (12.5% vs. 21.4%, <em>P</em> = .013) and less likely to have a BRAF mutation (1.5% vs. 16.1%, <em>P</em> = .002). BRAF mutation status was highly associated with MMR status; BRAF-mutated tumors were 29.7 times more likely than BRAF-WT tumors to be dMMR/MSI-H (<em>P</em> = &lt; .001, 95% CI 11.3-78.3).</p></div><div><h3>Conclusions</h3><p>Tumors of younger patients were less likely than tumors of older patients to have a dMMR/MSI-H or BRAF mutation. Universal MMR/MSI testing in our dataset identified a relatively large population of older patients with sporadic CRC who were eligible for immunotherapy.</p></div>","PeriodicalId":10373,"journal":{"name":"Clinical colorectal cancer","volume":"22 1","pages":"Pages 153-159"},"PeriodicalIF":3.4,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9151888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GI Symptoms in Pancreatic Cancer","authors":"Victor T. Chang ,&nbsp;Christopher Sandifer ,&nbsp;Fengming Zhong","doi":"10.1016/j.clcc.2022.12.002","DOIUrl":"10.1016/j.clcc.2022.12.002","url":null,"abstract":"<div><p><span>This review will apply a multidisciplinary approach to GI symptoms with attention to symptom assessment (instruments and qualitative aspects), differential diagnosis, and recent findings relevant to management of symptoms and underlying </span>diseases. We conclude that further development of supportive interventions for GI symptoms for both patient and caregivers has the potential to reduce distress from GI symptoms, and anticipate better symptom control with advances in scientific knowledge and improvement of the evidence base.</p></div>","PeriodicalId":10373,"journal":{"name":"Clinical colorectal cancer","volume":"22 1","pages":"Pages 24-33"},"PeriodicalIF":3.4,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9152924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term Survival Update and Extended RAS Mutational Analysis of the CAIRO2 Trial: Addition of Cetuximab to CAPOX/Bevacizumab in Metastatic Colorectal Cancer","authors":"Sanne ten Hoorn ,&nbsp;Linda Mol ,&nbsp;Dirkje W. Sommeijer ,&nbsp;Lisanne Nijman ,&nbsp;Tom van den Bosch ,&nbsp;Tim R. de Back ,&nbsp;Bauke Ylstra ,&nbsp;Erik van Dijk ,&nbsp;Carel J.M. van Noesel ,&nbsp;Roy J. Reinten ,&nbsp;Iris D. Nagtegaal ,&nbsp;Miriam Koopman ,&nbsp;Cornelis J.A. Punt ,&nbsp;Louis Vermeulen","doi":"10.1016/j.clcc.2022.11.006","DOIUrl":"10.1016/j.clcc.2022.11.006","url":null,"abstract":"<div><h3>Background</h3><p>Here we present updated survival of the CAIRO2 trial and assessed whether the addition of anti-EGFR to anti-VEGF therapy could still be an effective treatment option for patients with extended <em>RAS</em>/<em>BRAF</em> wildtype and left-sided metastatic colorectal cancer (mCRC).</p></div><div><h3>Materials and Methods</h3><p>Retrospective updated survival and extended <em>RAS</em> and <em>BRAF</em> V600E mutational analysis were performed in the CAIRO2 trial, a multicenter, randomized phase III trial on the effect of adding cetuximab to a combination of capecitabine, oxaliplatin (CAPOX), and bevacizumab in mCRC.</p></div><div><h3>Results</h3><p>Updated survival analysis confirmed that the addition of cetuximab did not provide a benefit on either progression free (PFS) or overall survival (OS) in the intention-to-treat population. With the extended mutational analyses 31 <em>KRAS</em>, 31 <em>NRAS</em> and 12 <em>BRAF</em> V600E additional mutations were found. No benefit of the addition of cetuximab was observed within the extended wildtype group, even when selecting only left-sided tumors (PFS HR 0.96, p = 0.7775). However, compared to the original trial an increase of 6.5 months was seen for patients with both extended wildtype and left-sided tumors (median OS 28.6 months).</p></div><div><h3>Conclusion</h3><p>Adding cetuximab to CAPOX and bevacizumab does not provide clinical benefit in patients with mCRC, even in the extended wildtype group with left-sided tumors. However, in the extended wildtype group we did observe clinically relevant higher survival compared to the initial trial report, indicating that it is important to analyze a broader panel of <em>RAS</em> and <em>BRAF</em> variants using more recent sequencing techniques when assessing survival benefit after anti-EGFR therapy.</p></div>","PeriodicalId":10373,"journal":{"name":"Clinical colorectal cancer","volume":"22 1","pages":"Pages 67-75"},"PeriodicalIF":3.4,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9153563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancers of the Pancreas Update 2023","authors":"Jordan Berlin","doi":"10.1016/j.clcc.2023.02.002","DOIUrl":"10.1016/j.clcc.2023.02.002","url":null,"abstract":"","PeriodicalId":10373,"journal":{"name":"Clinical colorectal cancer","volume":"22 1","pages":"Page 1"},"PeriodicalIF":3.4,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9154484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CT-guided Radioactive 125I Seed Implantation for Abdominal Incision Metastases of Colorectal Cancer: Safety and Efficacy in 17 Patients","authors":"Hao Wang ,&nbsp;Hong-Bing Shi ,&nbsp;Wei-Guang Qiang,&nbsp;Chao Wang,&nbsp;Bai Sun,&nbsp;Ye Yuan,&nbsp;Wen-Wei Hu","doi":"10.1016/j.clcc.2022.10.004","DOIUrl":"https://doi.org/10.1016/j.clcc.2022.10.004","url":null,"abstract":"<div><h3>Introduction</h3><p><span>To retrospectively evaluate the safety and efficacy of computed tomography (CT)-guided iodine-125 (</span>¹²⁵<span>I) seed implantation for patients with abdominal incision<span> metastases from colorectal cancer.</span></span></p></div><div><h3>Materials and Methods</h3><p>Data of patients with abdominal incision metastases of colorectal cancer from November 2010 to October 2020 were retrospectively reviewed. Each incisional metastasis was percutaneously treated with ¹²⁵I seed implantation under CT guidance. Follow-up contrast-enhanced CT was reviewed, and the outcomes were evaluated in terms of objective response rate, complications, and overall survival.</p></div><div><h3>Results</h3><p>A total of 17 patients were enrolled in this study. The median follow-up was 18 months (range, 2.7-22.1 months). At 3, 6, 12, and 18 months after the treatment, objective response rate was 52.9%, 63.6%, 33.3%, and 0%, respectively. A small amount of local hematoma occurred in two patients and resolved spontaneously without any treatment. Two patients experienced a minor displacement of radioactive seeds with no related symptoms. Severe complications, such as massive bleeding and radiation injury, were not observed. No ≥ grade 3 adverse events were identified. By the end of follow-up, 14 patients died of multiple hematogenous metastases. The one-year overall survival rate was 41.6%, and the median overall survival was 8.6 months.</p></div><div><h3>Conclusion</h3><p>CT-guided ¹²⁵<span>I seed implantation brachytherapy is safe and feasible for patients with abdominal incision metastases from colorectal cancer.</span></p></div>","PeriodicalId":10373,"journal":{"name":"Clinical colorectal cancer","volume":"22 1","pages":"Pages 136-142"},"PeriodicalIF":3.4,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50194194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}